GelStat Corporation (GSAC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GelStat Corporation (GSAC) with AI Score 65/100 (Buy). GelStat Corporation focuses on researching, developing, and marketing over-the-counter healthcare products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026GelStat Corporation (GSAC) Healthcare & Pipeline Overview
GelStat Corporation operates in the consumer healthcare sector, developing and marketing over-the-counter products like GelStat Migraine and Chews 2 Lose. With a small team and focus on non-prescription solutions, the company faces competition from larger generic drug manufacturers and established consumer health brands in a fragmented market.
Investment Thesis
GelStat Corporation presents a high-risk, high-reward investment profile. The company's small market capitalization and limited resources make it vulnerable to market fluctuations and competitive pressures. A potential upside lies in the successful commercialization of its existing product line and the development of new OTC products. With a negative P/E ratio of -3.37 and a negative profit margin of -73.3%, the company's financial performance needs significant improvement. The company's beta of 1.26 indicates higher volatility compared to the market. Investors should carefully consider the risks associated with investing in a small, OTC-listed company with limited financial resources and a concentrated product portfolio.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B reflects the company's small size and limited market presence.
- P/E Ratio of -3.37 indicates the company is currently not profitable.
- Profit Margin of -73.3% highlights significant challenges in achieving profitability.
- Gross Margin of 70.3% suggests potential for profitability if operating expenses are managed effectively.
- Beta of 1.26 indicates higher volatility compared to the overall market.
Competitors & Peers
Strengths
- Patented GelStat Migraine formula.
- Established distribution network.
- Focus on over-the-counter products.
- Gross margin of 70.3% indicates potential profitability.
Weaknesses
- Small market capitalization.
- Limited financial resources.
- Negative profit margin.
- High dependence on a few key products.
Catalysts
- Upcoming: Potential FDA approval for new OTC products in development.
- Ongoing: Expansion of distribution network to new retailers and wholesalers.
- Ongoing: Increased marketing efforts to drive product awareness and sales.
Risks
- Potential: Intense competition from larger pharmaceutical companies.
- Potential: Stringent regulatory requirements and potential product recalls.
- Ongoing: Limited financial resources and potential need for additional funding.
- Ongoing: Dependence on a few key products and potential for declining sales.
- Potential: Product liability claims and associated legal expenses.
Growth Opportunities
- Expansion of Product Line: GelStat can expand its product line by developing new OTC products targeting specific health concerns. The market for OTC products is vast, with opportunities in areas such as pain management, digestive health, and immune support. Successful development and launch of new products could drive revenue growth and increase market share. The timeline for this growth opportunity depends on the company's ability to secure funding for R&D and navigate regulatory approval processes.
- Strategic Partnerships: GelStat can pursue strategic partnerships with larger pharmaceutical companies or distributors to expand its market reach and access new distribution channels. Collaborations could provide access to established sales networks and marketing resources, accelerating product adoption and revenue growth. The timeline for this growth opportunity depends on the company's ability to identify and secure suitable partners.
- E-commerce Expansion: GelStat can invest in expanding its e-commerce presence to reach a wider customer base and capitalize on the growing trend of online shopping. Developing a user-friendly online platform and implementing effective digital marketing strategies could drive online sales and increase brand awareness. The timeline for this growth opportunity depends on the company's ability to invest in technology and digital marketing resources.
- Geographic Expansion: GelStat can explore opportunities to expand its geographic reach by entering new markets outside of the United States. International expansion could provide access to new customer segments and diversify revenue streams. The timeline for this growth opportunity depends on the company's ability to navigate international regulatory requirements and establish distribution networks in new markets.
- Focus on Niche Markets: GelStat can focus on developing and marketing products for niche markets with specific health needs. By targeting underserved segments of the population, the company can differentiate itself from larger competitors and build a loyal customer base. The timeline for this growth opportunity depends on the company's ability to identify and understand the needs of specific niche markets.
Opportunities
- Expansion of product line.
- Strategic partnerships with larger companies.
- E-commerce expansion.
- Geographic expansion into new markets.
Threats
- Intense competition from larger companies.
- Stringent regulatory requirements.
- Changing consumer preferences.
- Potential product liability claims.
Competitive Advantages
- Patented GelStat Migraine formula provides some protection.
- Established relationships with retailers and distributors.
- Brand recognition among consumers seeking specific OTC solutions.
About GSAC
GelStat Corporation, headquartered in Palm City, Florida, is a consumer healthcare company engaged in the research, development, and marketing of over-the-counter (OTC) and other non-prescription consumer healthcare products. The company's portfolio includes GelStat Migraine, a patented product designed to provide pain relief from migraine headaches. Other products include Chews 2 Lose, an appetite suppressant gum intended as a diet aid; All Natural Speed, an energy supplement; and GelStat Sleep, a product formulated to alleviate sleep disorders and associated symptoms. GelStat Corporation distributes its products through a network of retailers, wholesalers, specialty distributors, and catalog merchandisers, utilizing both direct sales and external sales brokers. Founded with the aim of providing accessible consumer health solutions, GelStat Corporation has focused on developing and commercializing products that address common health concerns. The company's strategy involves identifying market needs and formulating products that can be sold directly to consumers without requiring a prescription. Despite its efforts, the company faces challenges in a competitive market dominated by larger players with greater resources and established brand recognition.
What They Do
- Researches and develops over-the-counter (OTC) healthcare products.
- Markets and sells non-prescription consumer health products.
- Offers GelStat Migraine for migraine pain relief.
- Provides Chews 2 Lose appetite suppressant gum.
- Sells All Natural Speed energy supplements.
- Offers GelStat Sleep for relief from sleep disorders.
- Distributes products through retailers, wholesalers, and distributors.
Business Model
- Develops and patents over-the-counter healthcare products.
- Manufactures or outsources the production of its products.
- Sells products directly to retailers, wholesalers, and distributors.
- Generates revenue through product sales.
Industry Context
GelStat Corporation operates within the competitive and highly regulated drug manufacturers - specialty & generic industry. This sector is characterized by intense competition, stringent regulatory requirements, and evolving consumer preferences. The market for over-the-counter (OTC) drugs and non-prescription healthcare products is substantial, driven by increasing consumer awareness and a desire for self-care solutions. However, companies like GelStat face challenges from larger, more established players with greater resources and broader distribution networks. The industry is also subject to regulatory scrutiny from agencies like the FDA, which impacts product development, manufacturing, and marketing activities.
Key Customers
- Retailers selling OTC healthcare products.
- Wholesalers distributing healthcare products.
- Specialty distributors focusing on specific product categories.
- Consumers seeking non-prescription health solutions.
Financials
Chart & Info
GelStat Corporation (GSAC) stock price: Price data unavailable
Latest News
No recent news available for GSAC.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GSAC.
Price Targets
Wall Street price target analysis for GSAC.
MoonshotScore
What does this score mean?
The MoonshotScore rates GSAC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Javier G. Acosta
CEO
Javier G. Acosta serves as the CEO of GelStat Corporation. Information regarding his detailed career history and educational background is not available in the provided data. As the managing executive of a small team of two employees, Acosta's role likely involves overseeing all aspects of the company's operations, from product development and marketing to sales and distribution. His leadership is critical to the company's ability to navigate the competitive consumer healthcare market and achieve its strategic goals.
Track Record: Due to the limited information available, it is difficult to assess Javier G. Acosta's specific track record at GelStat Corporation. However, as CEO, he is responsible for guiding the company's strategic direction and overseeing its day-to-day operations. Key milestones under his leadership would include product launches, distribution agreements, and any improvements in the company's financial performance. The success of GelStat Migraine and other OTC products would be indicators of his leadership effectiveness.
GSAC OTC Market Information
The OTC Other tier, also known as the Pink Market, represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no reporting requirements, meaning they may not be required to file financial statements with the SEC. This lack of transparency increases the risk for investors, as there is less information available to assess the company's financial health and operations. Companies in this tier are often speculative and may be subject to significant price volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial reporting requirements.
- Lack of regulatory oversight.
- High potential for fraud and manipulation.
- Significant price volatility.
- Illiquidity and difficulty in buying or selling shares.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Determine if the company is subject to SEC reporting requirements.
- Company has been in operation for several years.
- Company has a patented product (GelStat Migraine).
- Company has established relationships with retailers and distributors.
- Company has a functional website and contact information.
- Company's products are available for sale through various channels.
GSAC Healthcare Stock FAQ
What does GelStat Corporation do?
GelStat Corporation is a consumer healthcare company that researches, develops, and markets over-the-counter (OTC) and non-prescription healthcare products. Its product line includes GelStat Migraine for migraine relief, Chews 2 Lose for appetite suppression, All Natural Speed for energy supplementation, and GelStat Sleep for sleep disorders. The company distributes these products through retailers, wholesalers, specialty distributors, and catalog merchandisers, targeting consumers seeking accessible and convenient health solutions. GelStat's business model focuses on identifying market needs and formulating products that can be sold directly to consumers without requiring a prescription.
What do analysts say about GSAC stock?
As of March 17, 2026, there is no available analyst coverage or consensus on GSAC stock. This is likely due to the company's small market capitalization, OTC listing, and limited financial resources. Investors should conduct their own independent research and due diligence before investing in GSAC, considering the risks and opportunities associated with the company's business model and financial condition. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are not meaningful due to the company's current lack of profitability.
What are the main risks for GSAC?
GelStat Corporation faces several significant risks. These include intense competition from larger pharmaceutical companies with greater resources, stringent regulatory requirements and the potential for product recalls, limited financial resources and the need for additional funding, dependence on a few key products and the potential for declining sales, and potential product liability claims and associated legal expenses. Additionally, as an OTC-listed company, GSAC is subject to greater price volatility and liquidity risk compared to companies listed on major exchanges.
What are the key factors to evaluate for GSAC?
GelStat Corporation (GSAC) currently holds an AI score of 65/100, indicating moderate score. Key strength: Patented GelStat Migraine formula.. Primary risk to monitor: Potential: Intense competition from larger pharmaceutical companies.. This is not financial advice.
How frequently does GSAC data refresh on this page?
GSAC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GSAC's recent stock price performance?
Recent price movement in GelStat Corporation (GSAC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Patented GelStat Migraine formula.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GSAC overvalued or undervalued right now?
Determining whether GelStat Corporation (GSAC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GSAC?
Before investing in GelStat Corporation (GSAC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financial performance and operations.
- OTC listing increases the risk of investing in GSAC.
- Analyst coverage is not available for GSAC.